A randomised, double blind trial to assess the morphological and biological effects with Arimidex [anastrozole], compared to placebo when used as neoadjuvant treatment for patients with endometrial cancer.

Trial Profile

A randomised, double blind trial to assess the morphological and biological effects with Arimidex [anastrozole], compared to placebo when used as neoadjuvant treatment for patients with endometrial cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2016

At a glance

  • Drugs Anastrozole (Primary)
  • Indications Endometrial cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 13 Aug 2009 Planned number of patients changed from 60 to 170 and actual end date (31 Jul 2006) added as reported by ISRCTN: Current Controlled Trials.
    • 10 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top